{"id":55036,"date":"2023-03-21T15:05:28","date_gmt":"2023-03-21T14:05:28","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/ally-biotech-announces-acquisition-of-popular-thc-chill-pill-soft-gel-cap-line-from-desert-medical-campus-inc\/"},"modified":"2023-03-21T15:05:28","modified_gmt":"2023-03-21T14:05:28","slug":"ally-biotech-announces-acquisition-of-popular-thc-chill-pill-soft-gel-cap-line-from-desert-medical-campus-inc","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/ally-biotech-announces-acquisition-of-popular-thc-chill-pill-soft-gel-cap-line-from-desert-medical-campus-inc\/","title":{"rendered":"Ally Biotech Announces Acquisition of Popular THC \u201cChill Pill\u201d Soft Gel Cap Line From Desert Medical Campus, Inc."},"content":{"rendered":"
\n

\n\u201cThe Chill Pill provides a great delivery system for a consistently accurate dose. We are excited to add new products, expand our team, and bring science and technology to the expansion of business and the brand,\u201d said Ally Biotech VP of Business Development, Francis Baczek.<\/i>\n<\/p>\n

PAYSON, Ariz.–(BUSINESS WIRE)–#Cannabis<\/a>–Ally Biotech, a science-based company and provider of leading-edge bioactive cannabinoid delivery solutions, today announced the acquisition of the popular Chill Pill<\/a>\u2122 brand, an extensive line of soft, easy-to-swallow soft gel caps and all of its assets, from Desert Medical Campus, in an all-cash transaction.\n<\/p>\n

<\/a><\/p>\n

\nThe Chill Pill brand, founded in 2018 by Andrew Provencio at his Desert Medical Campus facility, offered the first THC soft gel cap on the market in Arizona. The product quickly gained dominance within its product category for both medical and adult use consumers, which it still maintains. The Chill Pill line is now distributed in nearly 40 licensed Arizona dispensaries.\n<\/p>\n

\nAlly Biotech is the cannabis science company behind the Lipofusion\u00ae delivery technology, considered the next generation of oral delivery technologies for the cannabinoid market. Their proprietary nano-liposomal technology protects bio-actives from degradation in the digestive system and provides effective and increased absorption on the cellular level.\n<\/p>\n

\nCompany President, Jim Mackowiak, said plans are underway to expand the Chill Pill line to include new products that are developed with highly bioavailable custom formulations. \u201cThe new wave of cannabis consumers value rapid-onset products that are consistent and safe,\u201d he said.\n<\/p>\n

\nThe company\u2019s VP of Business Development, Francis Baczek agrees.\n<\/p>\n

\n\u201cChill Pill provides a great delivery system for a consistently accurate dose. We are excited to add new products, expand our team, and bring our improved science and technology to the growth of our business and our brands,\u201d said Baczek. \u201cWe have seen tremendous success with the Chill Pill brand because consumers rely upon its products\u2019 accurate dosing, convenience, consistency, and predictable therapeutic effects. Ally Biotech will continue building upon our strong vision for both the medical and adult-use markets, and is well poised to expand the brand successfully.\u201d\n<\/p>\n

\nProvencio\u2019s long-time business partner and COO of Desert Medical Campus, Pam Donner, concurs. \u201cThe company is in good hands with the innovative team at Ally Biotech,\u201d she said.\n<\/p>\n

\nMackowiak added that the company has hired key Desert Medical employees and will continue to build a culture of excellence while supporting economic development in Payson, where the current facility is located.\n<\/p>\n

\nThe Chill Pill soft gel cap line includes:\n<\/p>\n